3/11
02:12 pm
srpt
Global $111+ Billion Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis 2024-2034 - Rapid Growth in Exon-Skipping Therapies Reflects Precision Medical Interventions Fueled by R&D [Yahoo! Finance]
Low
Report
Global $111+ Billion Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis 2024-2034 - Rapid Growth in Exon-Skipping Therapies Reflects Precision Medical Interventions Fueled by R&D [Yahoo! Finance]
3/8
05:56 am
srpt
Got $1,000? Buy These Hot Growth Stocks Before They Take Off. [Yahoo! Finance]
Low
Report
Got $1,000? Buy These Hot Growth Stocks Before They Take Off. [Yahoo! Finance]
3/7
12:13 am
srpt
Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT) [Yahoo! Finance]
Low
Report
Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT) [Yahoo! Finance]
3/5
06:21 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
3/4
09:57 am
srpt
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]
Low
Report
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst [Yahoo! Finance]
3/4
09:11 am
srpt
Science Continues To Outpace Commercialization Of Cell And Gene Therapies [Forbes]
Low
Report
Science Continues To Outpace Commercialization Of Cell And Gene Therapies [Forbes]
3/4
08:30 am
srpt
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Sarepta Therapeutics to Present at Upcoming Investor Conferences
3/2
07:28 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
3/2
12:10 am
srpt
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight [Yahoo! Finance]
Medium
Report
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight [Yahoo! Finance]
3/1
11:48 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at UBS Group AG from $164.00 to $167.00. They now have a "buy" rating on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at UBS Group AG from $164.00 to $167.00. They now have a "buy" rating on the stock.
3/1
05:24 am
srpt
Sarepta Therapeutics Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
Low
Report
Sarepta Therapeutics Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
2/29
06:16 pm
srpt
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/29
02:34 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
2/29
01:54 pm
srpt
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y [Yahoo! Finance]
Low
Report
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y [Yahoo! Finance]
2/29
01:32 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Royal Bank of Canada from $151.00 to $157.00. They now have an "outperform" rating on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Royal Bank of Canada from $151.00 to $157.00. They now have an "outperform" rating on the stock.
2/29
01:09 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
2/29
12:33 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Citigroup Inc. from $160.00 to $172.00. They now have a "buy" rating on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Citigroup Inc. from $160.00 to $172.00. They now have a "buy" rating on the stock.
2/29
11:04 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
09:19 am
srpt
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program [Yahoo! Finance]
2/29
09:10 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Barclays PLC from $141.00 to $185.00. They now have an "overweight" rating on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Barclays PLC from $141.00 to $185.00. They now have an "overweight" rating on the stock.
2/29
09:00 am
srpt
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
Medium
Report
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
2/29
08:21 am
srpt
Destroy Duchenne selects DNA Nanobots as Partner to Develop Non-Viral Gene Delivery Solution for Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Destroy Duchenne selects DNA Nanobots as Partner to Develop Non-Viral Gene Delivery Solution for Duchenne Muscular Dystrophy [Yahoo! Finance]
2/29
08:16 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Needham & Company LLC from $169.00 to $166.00. They now have a "buy" rating on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Needham & Company LLC from $169.00 to $166.00. They now have a "buy" rating on the stock.
2/29
05:40 am
srpt
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases [Yahoo! Finance]
Medium
Report
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases [Yahoo! Finance]
2/29
12:10 am
srpt
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]